Compugen Stock News

Walleye Capital LLC lessened its stake in shares of Compugen Ltd. (NASDAQ:CGEN) by 93.9% during the second quarter, Holdings Channel.com reports. The firm owned 10,173 shares of the biotechnology companys stock after selling 157,667 shares during the period. Walleye Capital LLCs holdings in Compugen were worth $84,000 as of its most recent SEC filing. Several []

Compugen Ltd. (NASDAQ:CGEN) Jefferies Financial Group upped their FY2021 earnings per share (EPS) estimates for shares of Compugen in a research report issued to clients and investors on Monday, November 15th. Jefferies Financial Group analyst C. Howerton now anticipates that the biotechnology company will post earnings of ($0.39) per share for the year, up []

Compugen Ltd. (CGEN) with the stream of -3.67% also noticed, India YPF Sociedad Anonima (YPF) encountered a rapid change of -0.35% in the last hour of Tuesdays trading session. Compugen The post Flashy Stock: Compugen Ltd. (NASDAQ:CGEN), YPF Sociedad Anonima (NYSE:YPF) appeared first on Stocks Equity .

A price cut from an analyst had some traders hitting the sell button.

A price cut from an analyst had some traders hitting the sell button.

Shares of Compugen (CGEN) plummeted 18% to close at $5.87 on November 12 after the Israel-based cancer immunotherapy company reported a loss for The post Compugen Posts Q3 Loss; Shares Drop 18% appeared first on Smarter Analyst .

In the last trading session, 6.19 million Compugen Ltd. (NASDAQ:CGEN) shares changed hands as the companys beta touched 2.28. With the companys per share price at $5.87 changed hands at -$1.29 or -18.02% during last session, the market valuation stood at $600.91M. CGENs last price was a discount, traded about -158.26% off its 52-week high Compugen Ltd. (NASDAQ: CGEN): Performance Report And Growth Forecast Read More »

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2021 Results - Earnings Call Transcript

Compugen (CGEN) announces an expansion of its collaboration agreement with Bristol Myers Squibb and a $20 million equity investment by the latter.

The company is deepening its partnership with Bristol Myers Squibb.

The stock price of Compugen Ltd. (NASDAQ: CGEN) increased by over 15% pre-market today.

HOLON, Israel, Oct. 1, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that new clinica

HOLON, Israel, Sept. 14, 2021 /PRNewswire/ -- Compugen Ltd.

HOLON, Israel, Aug. 26, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced t

Bio-Rad's equity position in a German pharma company is an asset many investors may not realize.